Investigational drug · Phase 2
Famitinib
Also called: SHR-1020
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent or Metastatic Cervical Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 5, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
77
Any phase or sponsor naming "Famitinib"
First trial start
2021
Apr 5, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Famitinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent or Metastatic Cervical Cancer
Approved drugs for the same conditions: Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Famitinib" as an intervention, largest first.
- A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical CancerNot yet recruiting
Qi ZhouAcademic, hospital or other
NCT07266350 · 1,300 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 30, 2028
Drug: Camrelizumab; Famitinib · For: Cervical Cancer Metastatic; Cervical Cancer Recurrent
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05582499 · 716 participants (planned) · Start Nov 1, 2022 · Primary completion Dec 31, 2027
Drug: Dalpiciclib; Pyrotinib and 30 more · For: Breast Neoplasm; Breast Cancer; Breast Tumors and 7 more
Sites: Shanghai, China
- SNF Platform Study of HR+/ HER2-advanced Breast CancerPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05594095 · 620 participants (planned) · Start Dec 30, 2022 · Primary completion Dec 1, 2025
Drug: PIK3CA inhibitor; AKT inhibitor and 17 more · For: Breast Neoplasm; Breast Cancer; Hormone Receptor Positive Tumor and 2 more
Sites: Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT05862064 · 606 participants (planned) · Start Jun 1, 2023 · Primary completion Jul 1, 2026
Drug: epirubicin,cyclophosphamide,paclitaxel,Carrelizumab; epirubicin,cyclophosphamide,paclitaxel · For: TNBC - Triple-Negative Breast Cancer
Sites: Shanghai, China
- Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT)Pivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT02390947 · 543 participants · Start Jan 2015 · Primary completion Feb 2019
Drug: Famitinib; Placebo · For: Colorectal Cancer Metastatic; Colorectal Cancer Recurrent
Sites: Hefei, China; Beijing, China; Chongqing, China · 44 sites in all
- A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05042375 · 450 participants (planned) · Start Sep 8, 2022 · Primary completion Dec 31, 2023
Drug: camrelizumab + famitinib; pembrolizumab and 1 more · For: Non-small Cell Lung Cancer
Sites: Bengbu, China; Hefei, China; Beijing, China · 80 sites in all
- Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical CancerPivotal-lookingActive, not recruiting
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04906993 · 443 participants · Start Jul 23, 2021 · Primary completion Jun 10, 2025
Drug: camrelizumab; famitinib malate; platinum-based chemotherapy · For: Cervical Cancer
Sites: Shanghai, China
- A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)Pivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT05999149 · 424 participants (planned) · Start Aug 20, 2023 · Primary completion May 30, 2026
Drug: Camrelizumab Plus Chemotherapy and Famitinib; Camrelizumab Plus Chemotherapy · For: TNBC - Triple-Negative Breast Cancer
Sites: Shanghai, China · 2 sites in all
- Neoadjuvant SNF Precision Therapy Phase IIIPivotal-lookingRecruiting
Fudan UniversityAcademic, hospital or other
NCT06913777 · 404 participants (planned) · Start Apr 8, 2025 · Primary completion Oct 15, 2026
Drug: Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinib; Chemotherapy (wP-EC) · For: Neoadjuvant Therapy
Sites: Shanghai, China
Fudan UniversityAcademic, hospital or other
NCT04355858 · 319 participants (planned) · Start May 1, 2020 · Primary completion May 1, 2023
Drug: SHR7390; Famitinib and 13 more · For: Breast Cancer; Metastatic Cancer
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial.
Jiang J, Wei Y, Yang B, et al. · EClinicalMedicine 2026
- Clinical Outcomes and Safety Profile of Camrelizumab Plus Famitinib in Persistent, Recurrent, or Metastatic Cervical Cancer.
Liu X, Hua B, Xia Y, et al. · Oncol Res 2026
- Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Anti-Angiogenic Tyrosine Kinase Inhibitors for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Systematic Review and Single-Arm Meta-Analysis.
Hu R, Li T, Luo Z, et al. · Cancer Med 2026
- PD-1 Inhibition With Camrelizumab in Cervical Cancer: A Systematic Review and Meta-Analysis.
Musheer A, Mannan MS, Khan MW, et al. · Am J Clin Oncol 2026
- Addition of angiogenesis inhibitors to CDK4/6 inhibitors and fulvestrant in hormone receptor-positive, HER2-negative advanced breast cancer.
Zhang M, Niu L, Lyu H, et al. · Chin Med J (Engl) 2026
- Efficacy at a cost: camrelizumab and famitinib within the expanding landscape of combination therapies.
Zumarraga-Lizundia T, Barquin-Garcia A, Madariaga A · Gynecol Pelvic Med 2026
Also in development for Recurrent or Metastatic Cervical Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- GEMPhase 35 trials
Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer
- JSKN033Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors
- AdebelimabPhase 22 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. · Advanced Solid Tumors, Recurrent or Metastatic Cervical Cancer
- GT101Phase 21 trial
Grit Biotechnology · Recurrent or Metastatic Cervical Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.